PSMA PET Imaging in Prostate Cancer Staging: Guiding Initial Diagnosis and Treatment Decisions
Panelists discuss how PSMA PET imaging plays a crucial role in the initial staging of prostate cancer, offering superior accuracy over conventional methods. Medical professionals consider factors such as diagnostic performance, tracer availability, and patient-specific characteristics when selecting appropriate PSMA PET agents. The integration of PSMA PET findings into clinical practice has led to more precise treatment planning, potentially improving patient outcomes. Pivotal trials have demonstrated the efficacy of various PSMA PET tracers in detecting prostate cancer metastases.
- Video content above is prompted by the following: Briefly discuss the role of PSMA PET imaging for initial disease staging for patients with prostate cancer, considerations for selecting PSMA PET imaging agents, and how imaging guides treatment decisions in this setting.
- What percentage of your newly diagnosed patients receive PSMA PET imaging, and what is your typical approach when using it in this setting?
- How does PSMA PET imaging guide initial disease staging?
- What do available data from pivotal trials demonstrate, and how do these findings influence your decisions in this setting?
- PSMA-PreRP – Illuccix (gallium Ga68 gozetotide) Hope et al. JAMA. 2021
- OSPREY – Pylarify (piflufolastat F18) Pienta et al. J Urol. 2021
- LIGHTHOUSE – Posluma (flotufolastat F18) Surasi et al. Eur Urol. 2023
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
